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Disclaimer 
The views expressed in this article are the personal views of the authors and may not be understood 
or quoted as being made on behalf of or reflecting the position of the agencies or organizations with 
which the authors are affiliated. 
 
Abstract 
Paediatric Strategy Forums have been created by the multi-stakeholder organisation, ACCELERATE, 
and the European Medicines Agency to facilitate dialogue between all relevant stakeholders and 
suggest strategies in critical areas of paediatric oncology drug development. As there are many 
medicines being developed for B-cell malignancies in adults but comparatively few in children with 
these malignancies, a Paediatric Strategy Forum was held to discuss the best approach to develop 
these products for children. It was concluded that as current frontline therapy is highly successful, 
despite associated acute toxicity, de-escalation of this or substitution of presently used drugs with 
new medicines can only be undertaken when there is an effective salvage regimen, which is currently 
not available. Therefore priority should be given to developing treatment for patients with relapsed 
and refractory mature B-cell lymphomas. The consensus of the clinicians attending the meeting was 
that CAR T-cells, T-cell engagers and antibody drug conjugates (excluding those with a vinca alkaloid-
like drug) presently have the greatest probability of providing benefit in relapse in view of their 
mechanism of action. However, as producing autologous CAR T-cells currently takes at least 4 weeks, 
they are not products which could be quickly employed initially at relapse in rapidly progressing 
mature B-cell malignancies but only for the consolidation phase of the treatment. Global, industry 
supported, academic sponsored studies testing simultaneously compounds from different 
pharmaceutical companies should be considered in rare populations and it was proposed that an 
international working group be formed to develop an overarching clinical trials strategy for these 
disease groups. Future Forums are planned for other relevant paediatric oncologic diseases with a 
high unmet medical need and relevant molecular targets. 
 
Keywords: Paediatric oncology, mature B cell malignancies, medicinal product development 
 
 
 
 
Introduction 
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Currently, there are many developments in the field of oncology medicine with more effective and 
innovative medicinal products becoming available more rapidly to treat adult patients. Meanwhile, 
children in need of new therapeutic options still do not have access to early clinical studies leading to 
paediatric approvals1 and therefore do not have timely access to many of these innovative drugs. The 
high unmet medical need remains, and major efforts are being made to accelerate new drug 
development for children and adolescents with cancer. In parallel there are strong arguments that 
drug development for children with cancer should not be any different from adults and follow a 
mechanism of action-based approach rather than being driven by the adult indication for the 
medicinal product2. In light of this, in 2015, the European Medicines Agency revised their decision on 
class waiver3 list to allow an early dialogue with pharmaceutical companies on their paediatric 
development plans based on a mechanism of action approach. This approach is expected to further 
enhance timely development of paediatric oncology medicines. Highlighting the need of a global 
effort, the passing of the FDA Reauthorization Act of 2017 by the US Congress (and incorporating the 
RACE for Children Act), requires that “development of drugs and biological products should be 
evaluated early in paediatric cancers if the drug is directed at a molecular target substantially relevant 
to the growth or progression of a paediatric cancer”4 and is a substantial step along this path.  
 
Within this landscape there is a need to facilitate dialogue and provide an opportunity for constructive 
interactions between relevant stakeholders (clinicians, academics, patient representatives, 
pharmaceutical companies and regulators) on topics requiring open discussion, in the best interests 
of children and adolescents with cancer. To fulfil this need, the ACCELERATE multi-stakeholder forum, 
which aims to promote innovation in new drug development for children with cancer, and the EMA, 
have created Paediatric Strategy Forums. The goal of these meetings is to share information between 
all stakeholders, in a pre-competitive setting, to inform paediatric drug development strategies. This 
will facilitate the timely development and prioritisation of innovative medicines for the treatment of 
children with cancer, and make new drugs available for children more rapidly and ultimately introduce 
these medicines into standard-of-care treatment. The premise that scientific information should 
underpin these discussions and that no regulatory decisions would be made during the meeting was 
considered critical to the success of the Forums.  
 
As the objective of the Forum is to provide an opportunity for interaction and discussion between all 
stakeholders on topics being identified as hurdles or problems in drug development in children and 
adolescents with malignancy, two types of forum were envisaged; some focusing on a given molecular 
target and others on a disease. The first Paediatric Strategy Forum was held on 30-31 January 2017 at 
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the EMA on anaplastic lymphoma kinase inhibition in paediatric malignancies5. This pilot Forum 
demonstrated that the approach taken for the Paediatric Strategy Forums is feasible, can be highly 
relevant for paediatric cancer drug development and is widely supported by the participating 
stakeholders.  
 
There are many medicines being developed for B-cell malignancies in adults; however most of the 
malignancies in adults differ from those in children. Furthermore, the paediatric B-cell malignancy 
population is rare, with relapsed patients even rarer, as the current four year event free survival rates 
for children with newly-diagnosed mature B cell malignancies is greater than 90%6-12. Thus, 
ACCELERATE and the EMA agreed that it would be appropriate to dedicate the second Forum to 
discussing approaches to developing the best medicines for children with mature B-cell malignancies.  
The main aim of the forum was to share information, in a pre-competitive setting, to facilitate the 
developments of innovative medicines for the treatment of children with mature B cell malignancies.  
In the Forum the epidemiology, clinical features, biology, similarities and differences compared to 
adult mature B cell malignancies, current international standard approaches and therapeutic needs of 
mature B cell malignancies were presented. The medicines for mature B cell malignancies in 
development, relevant pre-clinical data and data from paediatric clinical trials completed or in 
progress, sponsored by industry or academia, were reviewed.  
 
The challenge of mature B cell malignancies in children and adolescents 
Mature B-cell malignancies in children and adolescents comprise Burkitt lymphoma, diffuse large B 
cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBL) and post-transplant 
lymphoproliferative disorders. The current standard of care for Burkitt lymphoma and DLBCL with 
standard-risk and high-risk disease results in more than 94% five year event free survival (EFS)6-12. 
Furthermore, similar results are currently observed in the Lymphoma Malignancy B-cell (LMB) and 
Berlin Frankfurt Munster (BFM) studies for B-cell non-Hodgkin’s lymphoma. Future discussions should 
therefore be on joining efforts for collaborative studies. On the other hand, the probability of survival 
for refractory and relapsed patients is very poor13,14. The acute toxicity (including infection) of current 
frontline treatment remains substantial, but evidence suggests that most survivors have limited long 
term sequelae15,16. Therefore, the solutions to address the current unmet therapeutic needs for 
children with mature B-cell malignancies are twofold: i) to develop innovative treatments for incurable 
patients; predominantly those with disease progression or relapse but also patients with predisposing 
conditions, including those associated with reduced treatment tolerance, for example post-transplant 
lymphoproliferative disorders17  or immunodeficiency, and ii) to reduce the high acute toxicity of 
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current therapy without jeopardizing rates of cure. There are many medicines being developed for B-
cell malignancies in adults; however, most B-cell malignancies in adults differ from those in children 
making direct extrapolation impossible and therefore specific studies need to be carried out in the 
paediatric population.  
 
With this background the goals for the Forum were to identify which of the many potential new drugs 
would have the optimal probability of improving rates of cure in paediatric patients with chemo-
resistant disease, and to initiate a dialogue on plans to design and execute scientifically sound studies 
in a very small international population of children with relapsed mature B-cell malignancies. 
 
Format of the Paediatric Strategy Forum 
The Paediatric Strategy Forum was held over two days at the EMA, with an emphasis on facilitating 
discussion and consensus amongst the participants. A comprehensive overview of the epidemiology, 
biology, standard therapy, therapeutic needs and future therapeutic strategies for paediatric patients 
with mature B-cell malignancies was provided by European and North American academic speakers. 
This gave context to the subsequent presentation of non-clinical and clinical information by 
pharmaceutical companies on medicinal products being developed, mainly in adults, for the treatment 
of B-cell malignancies. 
 
Prior to the Forum, the meeting preparation (over six months) included multiple planning phone calls 
with academic speakers and representatives of the pharmaceutical industry, ensuring an aligned 
approach to the meeting and its objectives. 
 
The Forum was advertised and expressions of interest were sought from the pharmaceutical industry 
(if they wished to present relevant medicinal products, a condition of their participation), academic 
clinicians and patient representatives. 
 
At the Forum, there were seventy three participants including European and North American experts 
in mature B-cell malignancies in children; drug development experts, representatives from fourteen 
pharmaceutical companies; patient representatives (from Childhood Cancer International, 
Unite2Cure, Children’s Cause for Cancer Advocacy); regulators from EU national competent 
authorities, EMA (including Paediatric Committee [PDCO]), Committee for Medicinal Products for 
Human Use [CHMP], Committee for Orphan Medicinal Products [COMP] and Scientific Advice Working 
Party [SAWP)] members) and the US Food and Drug Administration (FDA). 
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Mature B-cell malignancies in children 
Mature B-cell malignancies in children compared to adults 
Generally the spectrum, biology and nature of non-Hodgkin lymphoid malignancies in children differ 
from those in adults with the exception of PMBL. In children and adolescents younger than 14 years 
of age, 38-49% are Burkitt lymphoma, 7-20% DLBCL (with two subtypes – germinal centre [the 
majority] B-cell–like and activated B-cell–like), 21-29% lymphoblastic lymphoma, 10% anaplastic large 
cell lymphoma (ALCL), 1% follicular lymphoma and 2-11% other types18,19,20. In adolescents from 14 
years to younger than 19 years, 21-27% are Burkitt lymphoma, 21-37% DLBCL, 15-19% lymphoblastic 
lymphoma, 17-20% ALCL, 1% follicular lymphoma and 5-17% other types18,19,20. In total, mature B cell 
malignancies in children and adolescents (including Burkitt lymphoma, DLBCL and PMBL) comprise 
58% of all lymphomas with 98% being aggressive, and Burkitt lymphoma accounts for more than 80% 
of childhood B-cell malignancies. By contrast, in adults, 40% of non-Hodgkin lymphoid malignancies 
are follicular lymphoma, 30% DLBCL, 5% Burkitt lymphoma, 5% small lymphocytic lymphoma, 5% ALCL, 
5% lymphoblastic lymphoma and 10% other. Eighty percent of all lymphomas are B-cell lymphomas 
with 57% of those being indolent and the remainder being aggressive. In Europe and the US there are 
approximately just 1680 patients under the age of 19 years presenting each year with mature B-cell 
lymphomas, in contrast to about 200,000 adults18. Furthermore, there is good evidence that the 
biology and clinical behaviour of DLBCL in children differs from that in adults21 . The evidence is less 
clear that the biology and clinical behaviour of Burkitt lymphoma differs and probably is the same to 
the age of around 25 years22. 
 
Therapeutic targets for paediatric mature B-cell malignancies 
CD20, CD79a/b, CD19, CD22 and CD37 are pan B-cell markers which are expressed in essentially all 
mature B-cell malignancies. CD30 is expressed in a subset of mature B-cell malignancies, mostly DLBCL, 
and is associated with a better outcome in adult patients but not in children. CD30 is also expressed 
in PMBL, although more weakly than in Hodgkin disease. BCL2 and MCL1 could be targets in DLBCL 
and Burkitt lymphoma, respectively23. While chronic active B cell receptor (BCR) signalling is an 
activated B-cell–like DLBCL phenomenon, tonic BCR signalling (via the PI3K/AKT pathway) has a role 
in Burkitt lymphoma and some germinal centre-DLBCL. P53 pathway re-activation could in theory be 
effective in improving outcomes. PMBL has attractive targets such as PDL1/PDL2, with published 
experience of the efficacy with anti-PD1 immune checkpoint inhibitors24 (Table 1). 
 
Current therapy of mature B-cell malignancies in children and adolescents at presentation  
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In newly-diagnosed paediatric patients with standard-risk disease, frontline therapy is very effective 
and similar excellent results have recently also been achieved for patients with high-risk disease. The 
current therapy for paediatric high-risk mature B-cell malignancies (Burkitt lymphoma and DLBCL) 
consists of multi-agent chemotherapy and rituximab. The Inter B non-Hodgkin’s lymphoma (NHL) 
RItux 2010 study, which recruited 310 children and adolescent patients from Europe, the US and Asia, 
randomised patients to LMB chemotherapy with or without six doses of rituximab. The trial resulted 
in one year EFS of 94.2% (88.5% - 97.2 %; 95%CI), which is similar to other first-line protocols in 
standard risk B-cell NHL and for lower stage disease10. The NHL-BFM experience with rituximab added 
to chemotherapy has a very similar EFS >90%12. Acute toxicity is, however, high for both the Inter B 
NHL Ritux 2010 and NHL-BFM regimens. The future objectives for the treatment of these types of 
lymphomas are therefore to reduce toxicity and identify patients who are at high risk of recurrence or 
treatment failure. The results from three international groups for PMBL all demonstrate an inferior 
survival of 65-70% for children with PMBL24,25,26. More recently, the Inter B NHL Ritux 2010 phase II 
trial reported a similar EFS of 72% with DA-EPOCH-R27. Since PMBL harbours 9p21.1 alterations, this 
makes them vulnerable to PD1 blockade, and a randomised trial of a checkpoint inhibitor could, 
therefore, be a rational therapeutic approach in PMBL. 
 
Therapeutic needs of mature B-cell malignancies in children at relapse 
Based on the success of current first-line therapy discussed above, it is expected that in Europe and 
the US, there are only approximately 90 patients under the age of 19 years with relapsed/progressive 
disease, potentially eligible for early phase clinical studies each year; approximately 56 with Burkitt 
lymphoma, 17 with DLBCL and 14 with PMBL28. As the numbers of patients are so small, only 
international studies can generate useful data. As young adults and children with relapsed Burkitt’s 
lymphoma may have a similar biology29, they could be included in the same trials. Generally, following 
relapse, disease progresses quickly, response rates are between 50-60%, with very low probability of 
survival (EFS <30%)13,14. Single agent studies are challenging as patients who do not respond usually 
die rapidly and may have significant morbidity at the time of relapse. Disease refractory to or 
progressing on front-line therapy occurs very rarely (for DLBCL/Burkitt lymphoma <2.5%)7,30 with a 
very low survival rate, and the clinical consensus is that the biology in such patients is probably 
different from that seen in patients with relapsed disease, though biological studies comparing 
relapsed and refractory disease are lacking31. New medicinal products are being tested in patients with 
relapsed or refractory mature B-cell NHL. For example SPARKLE (NCT02703272), a randomised study 
of ibrutinib, a Bruton’s tyrosine-kinase (BTK) inhibitor, opened in July 2016 and aims to recruit 93 
subjects. Patients are being randomised to three courses of rituximab, ifosfamide, carboplatin and 
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etoposide with dexamethasone (RICE) or rituximab, vincristine, ifosfamide, carboplatin and idarubicin 
with dexamethasone (RVICI) with or without ibrutinib32. Results are expected by June 2021.  
 
Medicinal products for mature B cell malignancies developed for adults and relevant for treatment of 
malignancies in children 
In adults with DLBCL, rituximab has made a major impact33; however, dose escalation has not 
improved results in the majority of subtypes34. Furthermore, the benefit of second generation anti-
CD20 antibodies has not been clearly demonstrated35. Many new medicinal products have been 
demonstrated to be beneficial in low grade tumours36, and antibody conjugates and CAR-T cells have 
been demonstrated to be effective in higher grade tumours37.  
 
Within the Forum, eight classes of medicinal products were discussed: antibody drug conjugates, CAR 
T-cells, monoclonal antibodies, T-cell engagers, checkpoint inhibitors, cell signalling inhibitors, 
immunomodulatory imide drugs (IMiDs) and CELMoDs and cytotoxics (Table 2). 
 
Paediatric Investigation Plans (PIPs) 
According to Paediatric Regulation (EC) No 1901/2006 all applications for marketing authorisation 
(MA) for new medicines must include the results of studies carried out as part of an agreed PIP or 
information on a PIP deferral (for studies planned to be performed after the MA in adults) or a waiver  
A PIP is a development plan aimed at ensuring that the necessary data are obtained through studies 
in children to support the authorisation of a medicine for children. 
 
By November 2017 there were 13 PIPs agreed or under assessment for medicines for a condition 
related to the treatment of mature B-cell neoplasms. These medicines are: ibrutinib, acalabrutinib, 
idelalisib, nivolumab, obinutuzumab, pixantrone, pembrolizumab, pralatrexate, rituximab, venetoclax 
and three cellular therapies with autologous T-cells genetically modified to express a chimeric antigen 
receptor targeting CD19 (CD19 CAR T cell therapies) (tisagenlecleucel [CTL019], axicabtagene 
ciloleucel [KTE-C19] and JCAR017 [lisocabtagene maraleucel]). None of these PIPs have been 
completed and no final compliance check yet conducted. 
 
 
 
Discussion  
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The data presented demonstrated that the frequency of the types of B-cell malignancies differs 
between adults and children and in many instances the biology varies. The number of patients in 
Europe and the US eligible for clinical trials is substantially less for children and adolescents (1680 
versus 200,000 adults per year), especially those with relapsed or progressive disease (in the region 
of 90 patients per year). Furthermore, the number of patients with relapsed or progressive disease 
can be expected to fall significantly as a result of the decreased treatment failures with rituximab 
therapy for high risk disease.  
 
As a general principle¸ it was agreed that depending on the target, whenever possible, knowledge and 
protocols should be shared between related diseases in adults and children. However, with the 
exception of PMBL (where the disease is similar in adults and children), paediatric-specific studies are 
considered necessary. As mature B-cell lymphomas occurring in adults and children have different 
molecular pathologies, extrapolation of efficacy from adult to children is not appropriate in most cases 
and extrapolation of safety is not possible. Additionally, since children can tolerate higher doses, there 
is a risk of under-treating children if ‘adult’ doses are used or of increasing toxicity in adults, if 
‘paediatric’ doses are used. Therefore, the only opportunities may be for combined paediatric and 
adult frontline and relapsed clinical trials in PMBL, since the proposal is  to add a checkpoint inhibitor 
to “adult” and “paediatric” standard of care for each relevant age population. It should be noted that 
the logistics of conducting a joint frontline adult and paediatric study would not be without challenges. 
 
The inclusion of adolescents (aged 12 to 17 years) in adult trials of B-cell malignancies, where 
appropriate, is very strongly encouraged in this context, as adolescents demonstrate similar toxicity 
profiles, maximum tolerated doses and pharmacokinetic parameters to adults38. Furthermore, young 
adults with relapsed Burkitt’s lymphoma should be included in strategies and trials for “paediatric” 
relapsed disease, as Burkitt’s lymphoma has a similar biology at least up to 25 years of age22 and 
adolescent and young adults have a similar tolerance of chemotherapy as children. Drugs that are 
highly effective in small biomarker based selected subpopulations of patients, for example germinal 
centre DLBCL, may not be amenable to classical randomised trials in unselected patient populations; 
under such circumstances biomarkers should first be identified and randomised trials in enriched 
populations should be considered.   
 
The consensus of the clinicians present at the Forum was that it was not feasible to have a joint 
approach to clinical trials for leukaemia and lymphoma given differences in disease biologies and 
therapeutic approaches. Furthermore, the results of a trial including both leukaemia and lymphoma 
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would not be informative to investigators and/or regulators (e.g. due to difference in biology of 
disease). In addition the distinct (and often separate) organisation of leukaemia and lymphoma 
treating clinicians and services, or the significant undersupply of some options (especially in the case 
of CAR T-cells) for leukaemia patients, means that introducing competition within the same trial for 
patients with different disease would not be acceptable. 
 
As current frontline therapy results in high rates of survival, de-escalation of treatment or substitution 
of drugs with new medicines can generally only be undertaken when there is an effective salvage 
regimen, which is currently not available.  Priority should therefore be given to developing new 
treatment for patients with relapsed mature B-cell lymphomas. A further factor supporting this 
approach is that there is no validated biomarker predicting relapse. Therefore new drugs for mature 
B cell malignancies in children and adolescents should be first evaluated in relapsed patients who have 
the highest unmet need, and not frontline. At the same time, studies should continue to aim to identify 
and validate biomarkers predictive of relapse. 
 
In view of the very small numbers of patients available for enrolment in studies at relapse, a global 
strategy for the development of products for relapsed mature B-cell malignancies in children and 
adolescents is required. Other challenges in designing trials in these relapsed mature B- cell 
lymphomas are the rapid progression of the disease, availability of very few pre-clinical models (and 
uncertainty about the optimal model), and limited opportunity for extrapolation from adults. 
Therefore, unless there are agents with outstanding activity (overall response rate >80%, given that 
an overall response rate with conventional chemotherapy of ~60% only translates to EFS of <30%) in 
a given early phase study, a single agent study in the relapsed setting is unlikely to be appropriate. 
Whilst it is thus more appropriate that a new agent is evaluated in combination rather than as 
monotherapy, the probable contributory benefit of each drug within the combination needs to be 
established. However, sequencing of an experimental agent evaluated immediately at relapse 
followed by experimental consolidation/maintenance could facilitate a quicker introduction of new 
drugs into first-line therapy. To advance knowledge and facilitate the choice of rational therapy based 
on the mechanism of action, trials for relapsed disease must integrate correlative biology studies to 
investigate resistance to therapy. Moreover, longitudinal relevant correlative studies are required as 
these will facilitate a better understanding of mechanisms of resistance and response. 
 
Based on lack of significant therapeutic benefit and/or concerns around safety, the consensus of the 
clinicians attending the Forum was that CAR T-cells, T-cell engagers and antibody drug conjugates 
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(potentially excluding those carrying a vinca alkaloid-like drug) had the greatest probability of being 
beneficial in relapsed/refractory patients in view of their mechanism of action. It was furthermore the 
experts’ opinion that given the uncertainties on their efficacy, new additional trials of cell signalling 
inhibitors, including BTK inhibitors, should not commence until the results of the SPARKLE trial33 were 
known (Table3), especially in view of the very small numbers of available patients. This should 
however not preclude discussions on the placing of any such novel compound within the evolving 
treatment landscape. Additionally, as currently autologous CAR T-cells take at least 4 weeks for 
production, they are not products which could be quickly employed initially at relapse in rapidly 
progressing mature B-cell malignancies but only for the consolidation phase of the treatment. 
However, third party products, such as “off-the-shelf" modalities with streamlined manufacturing and 
distribution may circumvent these limitations. This prioritised approach to trials of new agents will 
reduce the probability of multiple trials competing for the same patients and increase the likelihood 
of recruitment. 
 
Optimal drug development for new anti-cancer medicines demands collaboration and interaction 
between all stakeholders, with each contributing substantially to the process. Proposals for industry 
sponsored early phase studies should be developed by pharmaceutical companies in collaboration 
and conjunction with clinicians, who have expertise in the clinical context and the available 
populations for clinical evaluation. The input of international clinical trial cooperative groups is 
particularly valuable. These proposals should be for appropriate paediatric clinical studies, based on 
scientific rationale and should form the basis of PIPs38 in Europe. Clinicians and pharmaceutical 
companies further considered that an iterative, ‘life cycle’ approach could be adapted for mechanism 
of action-driven drug development, with the direction of drug development continually being 
reviewed following evolution of the data and science. Changes could be made to the PIP by 
modification procedures supported by scientific arguments. 
 
In Europe and the US serious concerns were also raised by  the clinicians and pharmaceutical 
companies present about the number of agreed PIPs, in view of the small number of eligible patients, 
and about the source of information provided to sponsors submitting PIPs as to numbers of patients 
eligible for enrolment and number of committed study sites. This may result in a surfeit of medicinal 
products developed for a very small group of paediatric patients and therefore limited availability of 
patients for clinical trials participation and duplication of effort. Discussions among clinicians, 
cooperative groups and pharmaceutical companies should take place before PIPs are proposed, to 
decide which compounds are most likely to succeed in the paediatric population with mature B-cell 
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malignancies. Relevant points from these discussions should be incorporated into the clinical study 
design and relevant regulatory applications. This will result in a better alignment between the required 
number of patients for proposed clinical trials, potentially available eligible patients and regulatory 
requirements. On the other hand it should be taken into account that oncology medicines have an 
extremely high attrition rate (only 5.1% of the drugs tested in Phase I studies were approved in 2006-
2015)39 and that reducing the number of medicines tested in paediatric clinical trials too much could 
result in no new drugs being approved for children. Parent representatives stressed the importance 
of a global strategy and this proposed approach. 
 
European, US and other international academic clinical cooperative groups should work closely 
together, guide pipeline discussions with industry to identify those products able to address the unmet 
medical need and undertake collaborative clinical studies (due to low patient number) in those 
products considered most promising to accelerate the development of new drugs. In addition to 
industry-initiated drug development, there are many benefits of conducting industry supported, 
academic sponsored studies with compounds from different pharmaceutical companies and different 
mechanisms of action using an adaptive design; however academic clinical trials supported by industry 
should be designed and conducted to a very high quality standard with “intent to file”, in order that 
clinical trial data can be used for licensing purposes and early input should be sought from regulators 
(through available procedures with the EMA’s PDCO and/or SAWP and FDA). A global industry 
supported academic sponsored study with compounds from different pharmaceutical companies 
using a master protocol in rare populations should ideally be considered. These principles may also be 
highly applicable to other rare paediatric cancers where international collaborative studies are 
necessary. As a result of the Forum, highlighting the need for continuous exchange beyond the Forum, 
an international working group is being formed by ACCELERATE, with academic and industry 
participants, to develop an overarching clinical trials strategy for medicinal products for the treatment 
of relapsed mature B cell malignancies in children and adolescents.  
 
Finally, this Paediatric Strategy Forum has demonstrated that it is feasible for clinicians and industry 
to reach agreement, in the presence of supportive regulators and parent/patient representatives, 
about the prioritisation of classes of compounds for relapsed or progressive mature B-cell 
malignancies in children. Continual dialogue between industry and academia is critical for optimal 
drug development of new anti-cancer medicines in children. Future Forums are planned for other 
oncologic paediatric diseases with a high unmet medical need and possible relevant targeted agents. 
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Table 3 - PMBL - primary mediastinal B cell lymphoma, 
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Tables  
 
Table 1  
 Target Type of B Cell Malignancy 
Cell surface markers CD20, CD79a/b, CD19, CD22 
and CD37 
All mature B-cell malignancies 
 CD30 PMBL and some DLBCL 
Cell signalling  B-cell lymphoma (BCL)-2 and 
MCL1 
DLBCL and Burkitt lymphoma 
 Phosphoinositide 3-kinase 
(PI3-K)/AKT pathway 
Burkitt lymphoma and some 
germinal centre-DLBCL. 
Immunological Checkpoint PDL1/PDL2 PMBL 
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Table 2 
Class of medicinal 
product 
Product Target Company 
Antibody drug 
conjugates 
Polatuzumab vedotin  CD79b Roche 
 Debio 1562l CD37 Debiopharm 
International 
CAR T-Cells  CTL019 
(tisagenlecleucel) 
CD19 Novartis* 
 KTE-C19 (axicabtagene 
ciloleucel) 
CD19 Kite pharma**  
Monoclonal 
antibodies  
Obinutuzumab  CD20 Roche 
    
T-cell engagers  Blinatumomab CD3-CD19 Amgen 
 RG6026 CD20-CD3 TCB Roche 
 RG7828 CD20-CD3 TDB Roche 
Checkpoint inhibitor Pembrolizumab  PD-1 receptor Merck 
 BMS-986016  LAG-3 BMS 
Cell signalling 
inhibitors  
Ibrutinib  Bruton’s tyrosine-
kinase  
Jansen 
 Acalabrutinib  Bruton’s tyrosine-
kinase  
Acerta Pharma 
 BAY1895344 ATR Bayer 
 BMS986158 BET BMS 
 Idelalisib  Phosphoinositide 3-
kinase (PI3-K) 
Gilead 
 Venetoclax B-cell lymphoma 
(BCL)-2 
AbbVie 
 Navitoclax BCL-2  AbbVie 
IMiDs and CELMoD  CC-122  Celgene 
 CC-220  Celgene 
Cytotoxic  Pixantrone  Servier *** 
 
 
  
24          Paediatric Strategy Forum for medicinal product development for mature B cell malignancies in children Modified 9-1-19 
 
Table 3 
Medicinal products with greatest probability 
of being beneficial in relapse in mature B-cell 
malignancies in children 
Scientific rationale 
CAR T-cells Mechanism of action with a rapid onset of 
effect 
Significant advance in relapsed/refractory 
leukaemias with same target. Potential to 
replace high dose therapy, which is required 
for cure of relapsed/refractory B-cell non-
Hodgkin’s lymphoma. 
T-cell engagers Mechanism of action with a rapid onset of 
effect. Immune cellular therapy with 
significant promise in leukaemias with shared 
targets for B-cell non-Hodgkin’s lymphoma. 
Antibody drug conjugates Mechanism of action with a rapid onset of 
effect. Immuno-chemotherapy has shown 
substantial efficacy in frontline high risk B-cell 
non-Hodgkin’s lymphoma in adults. Antibody-
conjugates could provide increased efficacy in 
relapsed/refractory patients who may have 
received naked antibody as frontline therapy.   
Checkpoint inhibitors Biology of PMLBL associated with enhanced 
target for checkpoint inhibitors similar to 
Hodgkin’s lymphoma  
    
Medicinal products  with lower probability of 
being beneficial in relapse in mature B-cell 
malignancies in children 
Scientific rationale 
Monoclonal antibodies Mechanism of action with a slow onset of 
effect - lack of significant therapeutic benefit. 
In future most relapsed/refractory patients 
will have received naked monoclonal 
antibodies as part of frontline therapy. Adult 
studies do not suggest that changes of 
antibody against the same target in 
relapsed/refractory setting are effective.  
Cell signalling inhibitors Mechanism of action with a slow onset of 
effect demonstrated in adults - lack of 
significant therapeutic benefit and uncertainty 
about activity of Bruton’s tyrosine-kinase 
inhibitors (ongoing trial)  
IMiDs and CELMoD Mechanism of action with a slow onset of 
effect demonstrated in adults - lack of 
significant therapeutic benefit 
Cytotoxics Mechanism of action not different from 
established cytotoxics used in therapy of 
mature B-cell malignancies in childhood 
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Text Box 
 
 
 Except for Primary Mediastinal B cell lymphoma and  potentially relapsed Burkitt’s Lymphoma, 
specific paediatric studies are needed primarily due to different biology 
 Inclusion of adolescents (aged 12 to 17 years) in adult trials is very strongly encouraged  
 Joint leukaemia-lymphoma clinical trials are not feasible 
 Current frontline therapy is very successful and de-escalation can only be undertaken with an 
effective salvage regimen 
 Priority should be directed at developing treatment for relapse 
 Single-agent studies are not feasible  
 As there are very small numbers of patients with relapsed disease, a global strategy is required  
 Trials for relapsed disease must integrate correlative biology studies 
 The consensus of clinicians is that antibody drug conjugates (excluding a vinca alkaloid drug); CAR-T 
cells (as takes 4 weeks for production - not products for initial use but only for consolidation) and T-
cell engagers have the greatest probability of being beneficial in relapse 
 In view of very small numbers of patients, new additional trials of cell signalling inhibitors should not 
commence until the results of the ongoing SPARKLE trial known; yet discussion need to continue on 
the placing of any novel therapy  
 
 Clinicians and pharmaceutical companies expressed concerns about the number of 13 related 
Paediatric Investigation Plans (PIPs) agreed / under assessments, in view of the small number of 
eligible patients and proposed that PIPs being adapted in response to new data (‘PIP development 
Life-cycle’ approach) 
 Benefits of conducting academic sponsored clinical trials with adaptive design of compounds from 
different pharmaceutical companies and different mechanism of action  - designed with “intent to 
file” with  early input from regulators  
 Patient representatives stressed the importance of a global strategy in order to limit the possibility 
of having too  many PIPs for too few children 
